Peer Review History
Original SubmissionDecember 29, 2019 |
---|
PONE-D-19-35907 Motivational interviewing to support modifiable risk factor change in individuals at increased risk of cardiovascular disease: a systematic review and meta-analysis. PLOS ONE Dear Mr Mifsud Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ============================== Please revise your manuscript. As academic editor, my evaluation is that the paper is suitable for publication in PLOS ONE subject to changes, as indicated in the reviewers' comments, below. Please address all comments. If you disagree with any comments, please present your arguments/make your case in your rebuttal letter when you submit your revised manuscript. ============================== We would appreciate receiving your revised manuscript by 19 April 2020. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Maggie Lawrence Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements: 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf and http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. We note that your systematic review search is restricted to articles published until August 2018. Please ensure that that you search is up to date and the systematic review/meta-analysis includes any studies published since then. 3. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. In your revised cover letter, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. We will update your Data Availability statement on your behalf to reflect the information you provide. 4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 5. We note that this manuscript is a systematic review or meta-analysis; our author guidelines therefore require that you use PRISMA guidance to help improve reporting quality of this type of study. Please upload copies of the completed PRISMA checklist as Supporting Information with a file name “PRISMA checklist”. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: I Don't Know Reviewer #2: No ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: No ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Thank you for the opportunity to review this manuscript (PONE-D-19-35907). The manuscript is a systematic review and meta-analysis to determine the effectiveness of motivational interviewing (MI) for supporting modifiable risk factor change in people at increased risk of cardiovascular disease (CVD). The abstract is structured using appropriate sub-headings and is concisely written. The initial background section states MI has not been well established and explored (line 56), which is a little misleading because there is a wealth of research investigating the use of MI with various health settings and the paper later refers to a recent systematic review on a similar topic. It might be worth adding some additional context to this statement e.g. what areas are poorly established and have not been explored? The introduction sets the scene for the review and outlines the role of lifestyle therapies in the prevention of CVD. The introduction also introduces MI and outlines some of the core features of the approach. Understandably this is a fairly concise overview of MI, but I wonder whether it would be worth adding something about how these features are used when working with ambivalence and supporting behaviour change. The introduction continues by highlighting a gap in the literature and stating how this review compliments other literature. The paper then provides a separate rationale section, which is a little unusual. I wonder whether this rationale content might be better embedded within the introduction section? The review question is appropriate, but could be a little concise (e.g. Our review sought Line 141). There is also a little blurring between effectiveness, strategies, and mechanisms. I wonder whether it might be clearer to present the aims as three bullet points: 1) effectiveness 2) characteristics 3) mechanisms? The methods section begins by stating the review aligns with PRISMA, which is good. Although, I could see the attached table in the supporting information section to check completeness. A search strategy section is provided, but this could be more transparent and possibly more accurate. The search strategy is rather difficult to read because of the way the information is presented. The use of brackets to group the databases accessed via EBSCO is useful, but this is not used for databases accessed via ProQuest. I could be wrong, but I also think there is some confusion between databases (e.g. MEDLINE) and database providers (e.g. EBSCO and ProQuest) because there is not a consistent approach to how these are presented. It might be useful to list the databases and put the provider in brackets (e.g. MEDLINE (ProQuest)). The use of key words/subject headings could also be more explicit and it is unclear whether Boolean operators and/or delimiters were used. I understand an example of the search strategy is provided in the supplementary information, but I was unable to access this. I would also suggest changing the term “concepts” (line 164) to “search terms” or similar. The study selection section refers to RCTs “a high body of evidence”, which is rather unusual language (line 185) and might benefit from re-wording. It also refers to filters being applied when using endnote (line 187), but it is unclear what these filters are and whether they are referring to the delimiters applied during the initial database search. The data extraction section makes reference to critical appraisal (lines 205-208), but this is rather confusing and might be better re-worded and placed within the risk of bias section further down the paper. The paper includes a study outcomes sub-heading, which might be unnecessary given the other text provided. This section also does not mention effectiveness, which is one of the main aims of the review. The results section outlines the search and screening results and provides a PRISMA flowchart. The PRISMA flowchart is a little unusual, but provides the necessary information. The results section then provides a summary of the study characteristics. It would be good to explain the differences in the RCTs (line 265), so readers learn a little more about the studies instead of having to refer to the table. Table two shows the study characteristics, but could be enhanced by providing details of the actual participants (e.g. gender, mean age) instead of reporting the inclusion/exclusion criteria used in the original studies. The effectiveness of MI in supporting modifiable risk factor change is reported comprehensively. A summary of MI component is also provided, but I am a little unsure how the 12 items were selected and wonder whether a more comprehensive reporting method might be better (e.g. TIDieR DOI: 10.1136/bmj.g1687). It might also be worth considering whether the studies being reviewed used any competence measures (e.g. MITI DOI: 10.1016/j.jsat.2004.11.001). The discussion and limitation section are clear and make relevant points. The conclusion is brief and accurate. Check wording (line 606) and consider amending “possess”. Overall, this is a really interesting topic and thorough systematic review. It will be of interest to a wide number of people and help inform practice/research. It does needs some minor revision before publication and could be written more concisely in places. Reviewer #2: Many thanks for inviting to review this manuscript. Overall,the topic is interesting but there are numerous weaknesses, lack of clarity, poorsynthesis of results and general inconsistencies throughout the manuscript thatmade it difficult to review it to the end. I have picked at sections and willgo ahead to provide some comments. I am happy to re-review the whole manuscriptwhen the authors have attended to the preliminary comments.The manuscript will immensely benefit from professional editingservice prior to resubmission. Abstract Pg 3 line 63-64: It is not clear why only manuscriptsfrom 2013 to August 2018 were explored. What about earlier studies or studiesdone since after August 2018. Introduction: The rationale for this review was not effectivelyestablished. Given that a previous review suggested primary research (page 5lines 116 – 118) why implement a review instead of a primary research. Rationale Page 6 line 125 – 127 (The impact of MI… has remainedsuboptimal) – provide citation Search strategy- page 7 It is not clear if the search strategy is adequate. Thereaders will benefit from search strategy/ies implemented in individual database/sand journal/s. EbSCO host a number of databases so a generic strategy cannotapply to all the databases in EBSCO. I wonder what informed the decision to doa separate search in BMJ and Plos Journals and not the numerous psychology andallied health journals. It is also strange that BMJ and Plos journals willreturn lots of articles whereas search in databases returned just a few numbers. It wasnot clear where the conference proceedings were searched (169) Study Selection – pg 8Line 183 – what does the authors mean by internationalstudies? Line 185… Not clear what high body of evidence means. Lines 190 – 191… Reference lists of identified studies weremanually search to identify further eligible publication - at what point wasthis done? Was this done only for the 7 included papers?How was disagreement between reviewers regarding studieseligibility dealt with?What was done where it was not declared in a study whetheror not people with established CVD were included? Dataextraction – pg 9 Lines 205- 207 … Could this be stated as one of thelimitations? Only 3/7 satisfied the items on the risk of bias tables. Again,consideration should be given to the relevance of each of the items to theoverall risk of bias outcomes. E.g. Is it possible to blind a personnel deliveryMI to group allocation?Risk of bias assessment and quality of evidence – pg 10It is great that assessment of risk of bias was done at theoutcome level but were there considerations to the relevance of each domain toindividual outcomes? Could GRADE rating be objectively executed when there notformal meta-analysis in majority of the outcomes? How was inconsistency,imprecision, indirectness and publication bias assessed? Datasynthesis – pg 10 There are three aspects of heterogeneity – conceptual/clinical,statistical, and methodological. Some aspect of methodological heterogeneity mayhave been dealt with by including only RCT. However, MI in this review werepart of broader interventions in different contexts. Therefore, transparent reporting and justification of how data are grouped for synthesis is essential tocompletely deal with the methodological and conceptual heterogeneity. Synthesis of results Apart from the implemented meta-analysis, there were no realattempt at synthesis of results but a mere corroboration of the results fromprimary studies, making this section bulky and cumbersome to understand. Inaddition, implementing alternative metric synthesis means alternative questionswere answered. Although, this was mentioned in passing in the data synthesis section, the authors did not reflect this in reporting result synthesis. Indeed,meta-analysis asks the question of what is the size of the average effect. Onthe other hand, methods like summarising effect estimates only answer thequestion of the range and distribution of the effect. Combining p-values willshow if there is evidence that there is an effect in at least in one study.Lastly, vote counting based on direction(trends) of an effect teases out if thereis evidence of an effect? Therefore, the manuscript will benefit from a real synthesisand reporting that recognises these differences. Summary of outcome findings Similar to synthesis of results, the summary of outcomesfindings lumps everything together. For instance, it is not clear what wasbeing compared against MI for each of the outcomes – MI vs other behaviouralchange techniques, or MI vs usual care. In addition, the interpretation of the qualityof evidence did not reflect that each of the synthesis were not from ameta-analysis (as per the diver synthesis methods). Fig 1 - PRISMA flow diagram It is strange to see 2724 record excluded only by title reading leaving on 39 for abstract reading. It is typical to do title and abstract screening simultaneously because it may not be clear to remove many studies at the level of the title reading. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: Yes: Dr Ukachukwu Abaraogu Physiotherapy and Paramedicine School of Health and Life Sciences Glasgow Caledonian University Scotland United Kingdom [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step. |
Revision 1 |
PONE-D-19-35907R1 Motivational interviewing to support modifiable risk factor change in individuals at increased risk of cardiovascular disease: a systematic review and meta-analysis. PLOS ONE Dear Mr Misfud Thank you for submitting your manuscript to PLOS ONE. I am extremely sorry that it has taken me so long to get back to you. Busy workloads (mine and the reviewers’) following COVID 19 restrictions are in part to blame for this. Now that I have had time to consider the review comments of both the original reviewers and the statistical reviewer, I have revisited your paper with these comments in mind. I believe this is a good review which has merit, however after revisiting your paper, I find that does not fully meet PLOS ONE’s publication criteria as it currently stands and major revision is required before it meets publication standards. Some revisions are minor, others are major. I have listed these below. We invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Oct 19 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Maggie Lawrence Academic Editor PLOS ONE Additional Editor Comments (if provided): Dear Mr Misfud I am extremely sorry that it has taken me so long to get back to you. Busy workloads (mine and the reviewers’) following COVID 19 restrictions are in part to blame for this. Now that I have had time to consider the review comments of both the original reviewers and the statistical reviewer, I have revisited your paper with these comments in mind. I believe this is a good review and worthy of publication in PLOS One however after revisiting your paper, I find that major revision is required before it meets publication standards. Many are minor, some are more major. I have listed these below. Abstract In the Conclusion section that is a result - please remove that. Main body of the manuscript line 113 you refer to one systematic review and meta-analysis - please be clear about your meaning here. One review is about primary and secondary prevention, the other is not. Line 130 you refer to updating previous reviews - this is not accurate - the focus of your current review is narrower, please clarify. Line 161 after ‘electronic journals’ is everything in brackets an electronic journal or did you look at electronic journals within these resources? Please clarify. Line 164 I agree with the reviewers, the use of the word ‘concept’ is not useful here. It would be clearer to explain the PICOs elements (to use the term you use in Table 1) and then describe your search in terms of the PICOs elements. Line 180 are these ‘preventive interventions’ primary prevention interventions? Please clarify. Line 185 remove the word ‘but’ and replace it with ‘and’. Line 191 is it possible to conduct searches using Endnote? If not, remove the words ‘retrieved and’. Line 192 insert the word ‘potentially’ between the 'further’ and ‘eligible’. Table 1 insert ‘primary’ in your description of the Inclusion criteria for the Intervention element. line 212 I am aware that the reviewers suggested that you use the TIDieR checklist. The review would be more robust, I think, if you did used TIDieR to report the data extracted. You can add supplementary items, if you felt this was necessary but I haven't identified any items in sections 1) or 2) that would be supplementary. All would fit with TIDieR, item four, in particular. Also, I note you have used TIDieR in the Results section therefore it would make sense to also use it here. Lines 226 and 228 - swap the order of these two sentences. Line 223 do you mean ‘data extraction’ rather than ‘data abstraction’? Move the sentence to the data extraction section above and state that it was review specific or ‘adapted from...’ line 250 the heterogeneity paragraph in this location should be about methods only. The results element of this paragraph belongs in the Results section. Results Line 256 you report 1114 hits which after duplicates were removed reduced to 860. 792 records were then excluded – leaving a total of 68 - NOT 69 as stated. This mistake is replicated in the PRISMA flow diagram. Please check the numbers and amend both the text and the flow diagram accordingly. Table 2 Aadahl (2014) record complete the comment in the ‘control’ section Remove ‘both’ from after ‘gender’ in the Boutin-Foster, (2016) record. Insert 100% after ‘females’ in the Lin (2016) record Insert key to acronyms used in the table Line 303 the meaning here is unclear – either there was or wasn’t selective reporting. Line 306 surely there was reporting bias in what was reported (Tabel 3 indicates that this is the issue) and, if that is the case, it is not clear why you have singled out one study for comment. Line 312 replace ‘into’ with ‘to; ‘by’ is not the right word to use in this sentence. Line 314 – provide an example Line 322 remove ‘existent and’ Line 324 ‘outwith’ not ‘outwit’ Line 330 here and for all outcomes headings remove the information in brackets from the heading Line 368 – consider reporting this is such a way as to demonstrate that it is a positive finding. Line 414 why was a meta-analysis not doe for BP? After a bit of digging, I find it was because the results were reported in different was – it may be worth explaining that here – but also please note, the references are numbered incorrectly. Please check all reference numbering. Line 459 - what papers are being referred to in this section? Lines 479 – 481 How do you justify your interpretation of this finding? Is 73% ‘adequate’? Table 4 The meaning of the second row from the bottom is unclear I.e. Mean overall (%) reporting rate to at least one element Line 505 I think there is typo - ‘elements’ is used twice, and the meaning is unclear. Indicators paragraph This paragraph needs work the English could be improved and the paragraph would perhaps benefit from an explanatory opening sentence. For example, my understanding is that frequency of use of MI elements is mapped against intervention effectiveness. Is that right? This should be described in the methods section and not be making a first appearance here. Table 5 Presenting this aspect of your findings in this way is a good idea but I would be tempted to reduce this to include only the high-quality study columns - as these will be the results most likely to influence future practice, surely? The limitations section needs to include the issue of using English language papers only as this is not considered good practice. Reviewer 2 I note that reviewer 2 continues to argue that since the two previous reviews did not specifically focus on people without pre-existing CVD, findings from them should not represent results specific to people without pre-existing condition. I therefore suggest extending the search to older literature which focused on people without pre-existing CVD. I agree with reviewer 2 and think you either need to follow his suggestion or be clearer about this issue in the body of the text. Reviewer 3 Please address the issues raised by reviewer 3. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: (No Response) Reviewer #3: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: I Don't Know Reviewer #2: Yes Reviewer #3: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: (No Response) Reviewer #2: Authors have done well to address almost all my queries. However, I continue to argue that given the two previous reviews did not specifically focus on people without pre-existing CVD, findings from them should not represent results specific to people without pre-existing condition. I therefore suggest extending the search to older literature which focused on people without pre-existing CVD. Reviewer #3: interestimg paper. Abstract Definition of cochrane framework should be added Why from 8 studies for pnly 3 was analusis performed? Authors say that some features may be more likely like ...: how were these variables defined? Introduction is too long and should be shortened Methods: did authors performed sub analysis according to grading of paper Methods: did authors performed sub anakysis for grading of the paper Methods:authors spoke about conservative effect for random. This should be better specified Results: plots should be modified and made more consistent Discussion: high risk patients like hiv may be also interested by this procedure (quote on PMID: 26851703) ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: Yes: Dr Ukachukwu Abaraogu School of Health and Life Sciences Glasgow Caledonian University Reviewer #3: Yes: Fabrizio D'Ascenzo [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
Revision 2 |
Motivational interviewing to support modifiable risk factor change in individuals at increased risk of cardiovascular disease: a systematic review and meta-analysis. PONE-D-19-35907R2 Dear Mr Mifsud We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Maggie Lawrence Academic Editor PLOS ONE Additional Editor Comments (optional): Dear Mr Mifsud It was pleasure to read your paper this afternoon. I apologise again for it being such unextended process - but I believe your efforts and perseverance have resulted in an excellent, interesting paper of relevance to clinicians and researchers. This is robust work with which to underpin your empirical study. Reviewers' comments: |
Formally Accepted |
PONE-D-19-35907R2 Motivational interviewing to support modifiable risk factor change in individuals at increased risk of cardiovascular disease: a systematic review and meta-analysis. Dear Dr. mifsud: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Maggie Lawrence Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .